Back to Search Results
Jinjun Cheng Jinjun Cheng
Assistant Professor of Pathology
Assistant Professor of Pediatrics (Secondary)

Office Phone: 202-476-4311
Email: Email
Department: Pathology


  • MD Medicine, Anhui College of Chinese Medicine, 2002
  • Master of Science, Sun Yat-sen University of Medical Sciences, China, 2006
  • PH D, The University of Tennessee Health Science Center, 2012


Jinjun Cheng, MD, PhD, is an attending hematopahologist at Children's National Hospital (CNH), Washington, D.C., and an assistant professor in the Department of Pathology at The George Washington University School of Medicine and Health Sciences (GW). Prior to CNH and GW, he completed a hematopathology fellowship at the National Institutes of Health, Bethasda, M.D., and an Anatomical and Clinical Pathology Residency at the University of Tennessee Health Science Center, Memphis, T.N.

Clinical Expertise

Dr. Cheng's clinical practice focus is to provide diagnostic services in hematopathology. Aside from hematopathology service, he performs benign hematology and immunology service at CNH.



Dr. Cheng's research interest is centered on the genetic and immune microenvironmental pathobiology of hematopoietic neoplasms.




Toner K, Schore R, Cheng J. Mixed Phenotype Acute Leukemia with BCL11B Copy Gain: What is the best strategy? Pediatric Blood Cancer. Pediatric Blood Cancer. 2023 May 27:e30441. doi: 10.1002/pbc.30441.

Zhu, G, Inam Z, Calleroz A, Pillai V, Schore R, Cheng J. Pediatric Acute Erythroid Leukemia with Monocytic Antigen Expression and Novel Chromosomal Translocation. Pediatric Blood Cancer. 2023 Apr 19:e30333. doi: 10.1002/pbc.30333.

Zhou T, Cheng J, Karrs J, Davies-Hill T, Pack SD, Xi L, Tyagi M, Kim J, Jaffe ES, Raffeld M, Pittaluga S. Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma. Am J Surg Pathol. 2022 Oct 1;46(10):1364-1379. doi: 10.1097/PAS.0000000000001923. Epub 2022 Jun 1. PMID: 35650679; PMCID: PMC9481705.

Cheng J, Amin-Hashem M, Barabe F, Cloutier S, Xi L, Pittaluga S, Raffeld M, Jaffe ES. CCND1 Genomic Rearrangement as a Secondary Event in High Grade B-cell Lymphoma. Hemasphere. 2021 Jan; 5(1): e505. Cheng J, Klairmont MK, Choi JK. Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: highly reliable with rare exceptions. Pediatric Blood Cancer. 2019 Jan;66(1):e27453. doi: 10.1002/pbc.27453. Epub 2018 Sep 25.

Cheng J, Zhu HQ, Choi JK. CD30 Expression in Pediatric Neoplasms, Study of 585 Cases. Pediatr Dev Pathol. 2017; 20(3):191-196

de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, Obulkasim A, Dang J, Easton J, Verboon LJ, Mulder HL, Zimmermann M, Koss C, Gupta P, Edmonson M, Rusch M, Lim JY, Reinhardt K, Pigazzi M, Song G, Yeoh AE, Shih LY, Liang DC, Halene S, Krause DS, Zhang J, Downing JR, Locatelli F, Reinhardt D, van den Heuvel-Eibrink MM, Zwaan CM, Fornerod M, Gruber TA. Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia is Characterized by Distinct Genomic Subsets with Varying Outcomes. Nat Genet. 2017 Mar; 49(3): 451–456.

Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago- Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, FreiJones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11): 1005–1015.

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • None